Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort
Introduction
Falls are common in Parkinson's disease (PD) [1], [2], [3], [4], and both falls and postural instability negatively affect health-related quality of life in PD [5], [6], [7]. Persons with PD are about 3 times as likely to sustain a fall as their peers [8], and up to 50% of falls in PD result in injury [1], [2], [3], [9], [10]. Falls and fall-related injuries remain one of the top causes of increased health services utilization and costs for those with PD [11], [12], and preventing and treating balance problems was recently identified as the top PD research priority by 1000 participants in the United Kingdom who understood the issues of living with PD [13].
The most consistently reported risk factor for falls in PD is a prior history of falls [3], [4], [6], [14]. However, a meta-analysis of six prospective studies revealed that 21% of fallers had no history of falling [3], making it difficult to consistently identify at-risk individuals. Other factors associated with falls in PD include age, disease/motor severity measures, gait/axial impairments, self-rated disability, impaired cognition, fear of falling, and poor health-related quality of life, though these have been reported inconsistently [3], [4], [6], [14], [15], [16], [17], [18]. Most research on falls in PD has been conducted in older cohorts with a longer disease duration (> 5 years) [18], when freezing and postural instability are more prominent. Existing data on falls and falls risk is limited in early PD cohorts (< 5 years disease duration). Voss et al. analyzed two randomized, clinical trials of early, untreated PD patients and found that lower PD-related quality of life, age and prior history of falls were associated with falls [6]. A recent study followed 91 newly diagnosed, falls-naïve PD patients for 3 years and found that slower gait, shorter stance time and Hoehn-Yahr score of III were the most significant predictors of a first fall [17]. A better understanding of clinical risk factors that predict falls in early PD, other than a prior history of falls, would improve identification of those at risk of falling and guide interventions to prevent further falls.
We analyzed the National Institute of Neurological Disorders and Stroke (NINDS) Exploratory Trials in Parkinson's Disease (NET-PD) Long-term Study-1 (LS-1) data set [19], a large cohort of early (within 5 years of diagnosis), treated PD subjects. Because there are limited data on factors associated with falls in an early PD population but numerous factors correlated with falls in more advanced populations, we explored many possible associations. Our main aims were to determine the frequency of falling and to examine characteristics that separate fallers from non-fallers.
Section snippets
Subjects and assessments
The NET-PD LS-1 study enrolled 1741 participants in a large, randomized, multicenter, placebo-controlled trial of creatine as a potential disease modifying agent for PD [19]. All participants were within 5 years of PD diagnosis and on dopaminergic medication at least 3 months and < 2 years. Exclusion criteria included “any significant features suggestive of a diagnosis of atypical parkinsonism.” The study was terminated early due to an interim analysis that found no significant benefit of creatine
Results
Including baseline assessment, 728 (42%) of the 1741 subjects reported a fall at any point during the trial. Of these 728 subjects, 353 (48%) reported falls at only 1 visit, 157 (22%) reported falls at 2 visits, and 218 (30%) reported falls at three or more visits. 609 (35%) participants experienced falls based on the UPDRS items. 322 (18%) participants reported an adverse event related to falling, 119 (7%) of whom were not captured from the UPDRS questions. At baseline, 132 (8%) participants
Discussion
We analyzed a large, early PD clinical trial cohort (> 1700 subjects, mean ~ 1.5 years since diagnosis) being treated with dopaminergic therapy and found that over a median follow-up of 4 years, falls were common, occurring in 42% of participants. In a recent systematic review of 22 PD studies with prospective fall collection data, the proportion of subjects who fell ranged from 35 to 90%, with a mean of 60.5% [18]. Compared to the NET-PD LS-1 cohort, the majority of the studies included in this
Conclusions
Falls are common in early, treated PD, affecting approximately 40% of subjects in our analysis. The biggest risk factor influencing the probability of falling as well as fall rate remains a history of falling, even after adjusting for other characteristics. The strength of the association we observed is likely underestimated since we did not formally assess “history of falls” beyond UPDRS items at baseline or adverse effect reporting once a year. New findings in this study may explain previous
Author contributions
- (1)
Conception and design of the study: Chou, Elm, Aminoff, Liang, Hauser, Sudarsky, Voss, Juncos, Boyd, Bodis-Wollner, Morgan, Wills, Parashos; Acquisition of data: All authors; Analysis of data: Elm; Interpretation of data: All authors.
- (2)
Drafting the article: Chou, Elm, Parashos; Revising it critically for important intellectual content: All authors.
- (3)
Final approval of the version to be submitted: All authors.
Declaration of interest
Dr. Aminoff has received royalties from publishing Neurology & General Medicine (Elsevier, 1989–2015), Electrodiagnosis in Clinical Neurology (Elsevier, 1980–2015), Clinical Neurology (McGraw-Hill, 1989–2015), chapters in Cecil Textbook of Medicine (W.B. Saunders; 2004, 2008, 2012), Harrison's Principles of Internal Medicine (McGraw-Hill, 1994–2015), Handbook of Clinical Neurology (Elsevier; 2003–2015), The Netter Collection: Nervous System (Elsevier, 2013), Current Medical Diagnosis & Treatment
Financial disclosure/COI
The authors report no other financial disclosures related to the content of this manuscript.
Acknowledgements
The NET-PD LS-1 Trial Investigators were supported, in part, by grants U01NS043127, U01NS043128, and U10NS44415-44555 from the National Institute of Neurologic Disorders and Stroke.
References (23)
- et al.
Fall frequency and risk assessment in early Parkinson's disease
Parkinsonism Relat. Disord.
(2012 Aug) - et al.
Natural history of falls in a population-based cohort of patients with Parkinson's disease: an 8-year prospective study
Parkinsonism Relat. Disord.
(2014 Oct) - et al.
Impaired attention predicts falling in Parkinson's disease
Parkinsonism Relat. Disord.
(2009 Feb) - et al.
A community-dwelling sample of people with Parkinson's disease: characteristics of fallers and non-fallers
Age Ageing
(2001 Jan) - et al.
Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors
J. Neurol.
(2005 Nov) - et al.
A meta-analysis of six prospective studies of falling in Parkinson's disease
Mov. Disord.
(2007 Oct 15) - et al.
Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study
J. Neurol. Neurosurg. Psychiatry
(2002 Jun) - et al.
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial
Mov. Disord.
(2008 Apr 15) - et al.
Quality of life in Parkinson's disease: the relative importance of the symptoms
Mov. Disord.
(2008 Jul 30) - et al.
Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis
Epidemiology
(2010 Sep)
Fall risk factors in Parkinson's disease
J. Neurosci. Nurs.
Cited by (25)
The effect of galvanic vestibular stimulation on postural balance in Parkinson's disease: A systematic review and meta-analysis
2022, Journal of the Neurological SciencesCitation Excerpt :Falls are a significant predictor in determining the quality of life of PD patients and are one of the main causes of hospitalisation in these patients [35]. Dopaminergic therapy, the mainstay of PD treatment, is effective in improving the cardinal PD features of tremor, rigidity and hypokinesia, but its effects upon imbalance in PD is inconsistent [1,13]. Despite the relative lack of effect of dopaminergic therapy upon falls in PD, Dopamine appears facilitatory upon other interventions for imbalance [52], explaining the rationale for testing balance interventions in PD patients who are on stable dopaminergic replacement in the ‘ON’ state.
Physiotherapy management of Parkinson's disease
2021, Journal of PhysiotherapyCitation Excerpt :On the other hand, balance impairment could be caused by dysfunctions in the non-dopaminergic system, as it is often resistant to dopamine.7 The cardinal motor symptoms may give rise to a variety of secondary impairments such as muscle weakness (ie, reduced capacity of the muscles to generate force),8,9 altered gait (eg, reduced walking speed, stride length, cadence and level of independence in walking),9,10 reduced aerobic capacity (ie, reduced peak oxygen consumption rate and endurance)11–14 and falls.15,16 These secondary impairments, together with worsening of the motor symptoms as the disease progresses, may trigger a vicious cycle of further decline in physical activity level, activity and participation.
Using machine learning-based analytics of daily activities to identify modifiable risk factors for falling in Parkinson's disease
2021, Parkinsonism and Related DisordersCitation Excerpt :However, our study suggests that patient-related predictors of any fall are not the same as those of recurrent falls. The use of any anti-parkinsonian medication is not an important treatment-related feature to predict any falls, but the use of dopamine agonist has some influences on recurrent falls, consistent with prior literature [19]. In addition, our study reported a new finding that the use of COMTI was negatively associated with recurrent falls.
Recurrent falls in people with Parkinson’s disease
2020, Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1Exercise for Parkinson's disease
2019, International Review of NeurobiologyCitation Excerpt :Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease (Chou et al., 2017), affecting approximately 7 million people worldwide (Dorsey & Bloem, 2018).
Falls in Synucleinopathies
2020, Canadian Journal of Neurological Sciences